NEW YORK (GenomeWeb News) — CombiMatrix today reported preliminary revenue growth of 172 percent and 171 percent for billable prenatal tests in the fourth quarter of 2012 and full-year 2012, respectively.

In addition, the firm said that overall billable testing volumes, including its de-emphasized oncology segment, grew 21 percent and 25 percent in the quarter and full year, respectively, compared to its 2011 results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.